Systemic scleroderma is not directly inherited like a single-gene disorder, but genetics do play a role in making some people more susceptible. The overall concordance rate in twins is only about 4.7%, meaning that even among identical twins sharing the same DNA, if one twin has the disease, the other almost never develops it. What runs in families is not the disease itself but a genetic predisposition that, combined with environmental triggers, can tip the balance toward illness.
Family Risk Compared to the General Population
The general population prevalence of systemic scleroderma is roughly 19 per 100,000 people, or about 0.008%. Among people who have a first-degree relative with the disease, that prevalence rises to approximately 0.08%, which translates to a relative risk about 13 times higher than someone with no family history. That sounds dramatic in relative terms, but in absolute terms the risk is still less than 1 in 1,000.
The risk is not equal across all family relationships. Siblings of someone with scleroderma face the steepest increase, roughly 81 times the background risk. Children of affected parents have a smaller but still notable elevation, around 9 times the general population rate. A large familial study also found that autoimmune diseases in general tend to cluster in scleroderma families, suggesting shared genetic ground with conditions like lupus and rheumatoid arthritis.
What the Twin Studies Reveal
The clearest way to separate genetics from environment is to compare identical twins (who share virtually all their DNA) with fraternal twins (who share about half). In scleroderma, the concordance rate for actually developing the disease is similarly low in both groups, around 4.7%. That tells researchers that genes alone are not enough to cause the disease.
However, when researchers looked at autoantibodies, the immune proteins that attack the body’s own tissues, identical twins were far more likely to share those markers than fraternal twins. This means genetics strongly influence whether your immune system develops the abnormal antibodies seen in scleroderma, even if something else determines whether those antibodies ever progress to full-blown disease.
Specific Genes That Raise or Lower Risk
The most consistent genetic link involves a set of immune-system genes called HLA genes, which help your body distinguish its own cells from invaders. One variant, HLA-DRB1*11, has been identified as a risk allele for scleroderma, while another variant, DRB1*12, appears to be protective. In one study of familial cases, every affected family member carried the DRB1*11 variant and none carried the protective DRB1*12.
Beyond HLA genes, researchers have identified variants in genes involved in interferon signaling and immune regulation. These genes influence how aggressively the immune system responds to perceived threats. Carrying risk variants in several of these genes at once likely compounds susceptibility, but no single gene is sufficient to cause the disease on its own.
Why Women Are Affected Far More Often
Systemic scleroderma affects women roughly five times more often than men, with some populations showing ratios as high as 14.5 to 1. This disparity points to something beyond standard genetics: the X chromosome.
Women carry two X chromosomes, and normally one is silenced in each cell to prevent a double dose of X-linked genes. In women with scleroderma, this silencing process is often incomplete or skewed. Several immune-related genes on the X chromosome escape silencing, leading to overexpression of receptors that drive inflammation and interferon production, both central to scleroderma’s progression. One of these escaped genes helps stimulate both T cells and B cells, the immune cells responsible for attacking tissues and producing autoantibodies. The result is a more reactive immune system that is primed for autoimmune activity.
Recent research has also identified the silencing molecule itself, called XIST, as a potential trigger. The protein complex that XIST forms contains multiple components that the immune system can mistakenly target with autoantibodies. When researchers artificially expressed this complex in male mice, the animals developed immune profiles resembling those of females with autoimmune disease. Several of the proteins in this complex are known autoantibody targets in scleroderma patients.
Epigenetic Changes: Genes Without Mutations
Even when the DNA sequence itself is normal, the way genes are switched on or off can go wrong. These “epigenetic” changes are a major factor in scleroderma and help explain why identical twins rarely share the disease despite sharing the same genetic code.
The most studied mechanism is DNA methylation, a chemical tag that silences genes. In scleroderma patients, genes related to interferon signaling are under-methylated, meaning they are abnormally active and drive chronic immune activation. At the same time, genes that normally keep the immune system in check, like those controlling regulatory T cells, are over-methylated and effectively muted. This creates a double hit: the accelerator is stuck on while the brakes are weakened.
Epigenetic changes also affect the cells that produce scar tissue. In scleroderma fibroblasts, the cells responsible for collagen production, chemical modifications to the proteins that package DNA lead to overproduction of collagen. A gene called FLI1, which normally restrains collagen production, is dialed down through reduced acetylation of the proteins surrounding it. These epigenetic shifts can be influenced by environmental exposures, infections, and hormonal changes, which is why two people with the same genetic risk can have very different outcomes.
Environmental Triggers in Genetically Susceptible People
The prevailing model of scleroderma is that an environmental exposure triggers the disease in someone who is already genetically predisposed. The strongest evidence points to occupational exposure to silica dust and organic solvents. In one large Canadian cohort, about 7% of all scleroderma patients and roughly 20% of male patients reported silica exposure. Those with silica exposure were diagnosed at a younger age, had more severe lung and skin involvement, and had higher mortality.
The connection makes biological sense. Silica particles damage tissue and activate the immune system in ways that promote the exact inflammatory and scarring pathways already primed by scleroderma-related genes. For people with the right (or wrong) genetic background, this kind of sustained immune activation can cross the threshold into autoimmune disease. Other proposed triggers include certain viral infections and medications, though the evidence is strongest for silica and solvents.
How Vascular Damage and Fibrosis Develop
The genetic and epigenetic changes in scleroderma converge on two destructive processes: damage to small blood vessels and excessive scarring of tissues. Vascular injury comes first. The cells lining small blood vessels become damaged and begin transforming into scar-producing cells through a process driven by growth factors, particularly one called TGF-beta. This same growth factor also converts the support cells surrounding blood vessels into collagen-producing cells, amplifying the fibrosis.
As blood vessels narrow and scar tissue accumulates, organs receive less oxygen. The resulting low-oxygen environment further stimulates the production of a molecule that constricts blood vessels while suppressing the molecule that relaxes them. This creates a self-reinforcing cycle: vascular damage causes scarring, scarring worsens blood flow, and poor blood flow causes more damage. The genetic variants and epigenetic changes associated with scleroderma don’t cause this cycle directly, but they lower the threshold at which it can be triggered and make it harder for the body to interrupt once it starts.
What This Means for Families
If you have a relative with systemic scleroderma, your absolute risk of developing it remains low, well under 1%. The disease requires a convergence of genetic susceptibility, epigenetic changes, and environmental exposures that is unlikely to repeat exactly in another family member. There is no single gene test that can predict whether you will develop scleroderma, and routine genetic screening of family members is not standard practice.
What does cluster in families is a broader tendency toward autoimmune conditions. If scleroderma runs in your family, you may carry immune-related gene variants that also raise susceptibility to other autoimmune diseases. Being aware of this pattern can help you and your doctor interpret early symptoms, like unexplained Raynaud’s phenomenon (fingers turning white or blue in cold), persistent joint stiffness, or skin changes, with appropriate context rather than dismissing them.